![Trishna Goswami](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Trishna Goswami
Director Técnico/Científico/I+D en IN8BIO, INC. .
Fortuna: 8 008 $ al 31/05/2024
Cargos activos de Trishna Goswami
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
IN8BIO, INC. | Director Técnico/Científico/I+D | 16/11/2021 | - |
Historial de carrera de Trishna Goswami
Antiguos cargos conocidos de Trishna Goswami.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
IMMUNOMEDICS, INC. | Corporate Officer/Principal | 01/06/2018 | 01/12/2021 |
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2017 | 01/06/2018 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | - | - |
Formación de Trishna Goswami.
Drexel University College of Medicine | Doctorate Degree |
Robert H. Smith School of Business | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 7 |
Operativa
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
IN8BIO, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Immunomedics, Inc.
![]() Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Stemline Therapeutics, Inc.
![]() Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Trishna Goswami
- Experiencia